Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal D...( SAN DIEGO Jan. 20 /- (Nasdaq: W...)

SAN DIEGO, Jan. 20 /PRNewswire-FirstCall/ -- (Nasdaq: SQNM) Analyst and Investor Briefing and Reception

    What:     Sequenom: Defining the Future of Noninvasive Prenatal
              Diagnostics Analyst and Investor Briefing and Reception

    When:     Wednesday, January 28, 2009 from 5:30 p.m. to 8:00 p.m.

    Where:    www.sequenom.com/Corporate/Investor-Relations

    How:      Live over the Internet -- Simply log on to the Web at the
              address above.

    Contact:  Amy Higgins
              (310) 691-7100
              ahiggins@lhai.com

About Sequenom

Sequenom is committed to providing the best genetic analysis products that translate the results of genomic science into solutions for noninvasive prenatal diagnostics, biomedical research, translational research and molecular medicine applications. The Company's proprietary MassARRAY(R) system is a high-performance (in speed, accuracy and cost efficiency) nucleic acid analysis platform that quantitatively and precisely measures genetic target material and variations. The Company has exclusively licensed intellectual property rights for the development and commercialization of noninvasive prenatal genetic tests for use with the MassARRAY system and other platforms. Sequenom maintains a Web site at www.sequenom.com to which Sequenom regularly posts copies of its press release as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission (the "SEC") or posts certain other information to the Web site.

Sequen
'/>"/>